According to Ekaterina Zinovieva, Deputy Prime Minister and Minister of Investment, Industry, and Science of the Moscow Region, Alsigma has become a resident of the Dubna Special Economic Zone. As part of the investment project, a state-of-the-art research and production complex spanning an area of approximately 5,200 square meters will be established to facilitate the development and manufacturing of pharmaceuticals. Investments will amount to 780 million rubles. The project will create 55 jobs.
Alsigma will develop generics – drugs that contain the same active ingredient as original drugs. The project aims to establish the production of high-demand drugs in Russia, ensuring a consistent supply and reducing dependence on imported medications. The launch of the first stage is scheduled for 2027, the full implementation of the project – for 2029.
The company’s primary objective is to develop, produce, and launch antitumor hormonal drugs, hormone antagonists, and related compounds. The company also plans to conduct research and development in the area of discovering new promising antibiotics and oncological drugs, in collaboration with experts in the field of microbiology, clinical pharmacology, and other specialists in antibiotic therapy.